Advertisement
Screener

CAMP4 Therapeutics Corporation (CAMP) Graph

CAMP Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $1.78M; Research and development $10.82M; Operating expenses $15.16M; Income tax $0.00.
  • 2026-03-31: Revenue $1.29M; Research and development $10.16M; Operating expenses $14.37M; Income tax $0.00.
  • 2025-12-31: Revenue $348.00K*; Research and development $8.36M*; Operating expenses $13.12M*; Income tax $0.00*.
  • 2025-09-30: Revenue $795.00K; Research and development $9.36M; Operating expenses $14.45M; Income tax $0.00.

Counterparty Name

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

CAMP revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Bio MarinPharmaceutical Inc.$0.00FulcrumTherapeutics Inc.$600.00KGlaxo Smith Kline IntellectualProperty No.3Limited GSK$1.80MRevenue$1.78MOperating expenses$15.16MOperating income-$13.38MOther income, net-$27.00KResearch & development$10.82MIncome tax$0.00Net income-$33.53M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

CAMP revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.RD$1.78MRevenue$1.78MOperating expenses$15.16MOperating income-$13.38MOther income, net-$27.00KResearch & development$10.82MIncome tax$0.00Net income-$33.53M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$1.78M$10.82M$15.16M$0.00-$33.53M
2026-03-31$1.29M$10.16M$14.37M$0.00-$18.33M
2025-12-31$348.00K*$8.36M*$13.12M*$0.00*-$40.28M*
2025-09-30$795.00K$9.36M$14.45M$0.00-$15.10M
2025-06-30$1.50M$10.34M$14.53M$0.00-$12.59M
2025-03-31$858.00K$10.15M$13.96M$0.00-$12.43M
2024-09-30$0.00$9.70M$13.52M$0.00-$13.48M
2024-06-30$0.00$9.39M$12.66M$0.00-$12.57M
2024-03-31$0.00$9.74M$12.88M$0.00-$12.46M
2023-09-30$350.00K$9.82M$12.69M$0.00-$11.70M
2023-06-30(m)(m)(m)(m)-$12.10M
2023-03-31(m)(m)(m)(m)-$12.51M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$3.07M$20.98M$29.52M$0.00-$51.86M
2025-06-30$2.35M$20.49M$28.48M$0.00-$25.02M
2024-06-30$0.00$19.13M$25.54M$0.00-$25.03M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$3.15M$29.84M$42.93M$0.00-$40.12M
2024-09-30$0.00$28.82M$39.05M$0.00-$38.51M
2023-09-30$350.00K$29.95M$38.75M$0.00-$36.30M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$3.50M$38.20M$56.05M$0.00-$80.40M
2024-12-31$652.00K$38.82M$53.74M$0.00-$51.79M
2023-12-31$350.00K$40.62M$52.23M$0.00-$49.29M

Similar stocks

Stock NameCountryMarket CapPE Ratio
MACROGENICS INC (MGNX)United States$0.242B-20.11
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51